ECSP13012431A - Combinación del compuesto glyt1 con antipsicóticos - Google Patents

Combinación del compuesto glyt1 con antipsicóticos

Info

Publication number
ECSP13012431A
ECSP13012431A ECSP13012431A ECSP13012431A EC SP13012431 A ECSP13012431 A EC SP13012431A EC SP13012431 A ECSP13012431 A EC SP13012431A EC SP13012431 A ECSP13012431 A EC SP13012431A
Authority
EC
Ecuador
Prior art keywords
glyt1
combination
antipsychotics
compound
schizophrenia
Prior art date
Application number
Other languages
English (en)
Inventor
Jean-Luc Moreau
Joseph G Wettstein
Daniela Alberati
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44512856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP13012431A publication Critical patent/ECSP13012431A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica de un inhibidor del transportador de glicina (GlyT1) y un fármaco antipsicótico atípico que puede utilizarse para el tratamiento de los síntomas positivos y negativos de la esquizofrenia.
ECSP13012431 2010-08-09 2013-02-07 Combinación del compuesto glyt1 con antipsicóticos ECSP13012431A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10172316 2010-08-09

Publications (1)

Publication Number Publication Date
ECSP13012431A true ECSP13012431A (es) 2013-03-28

Family

ID=44512856

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012431 ECSP13012431A (es) 2010-08-09 2013-02-07 Combinación del compuesto glyt1 con antipsicóticos

Country Status (29)

Country Link
US (1) US20120035156A1 (es)
EP (1) EP2603219B1 (es)
JP (1) JP2013533297A (es)
KR (1) KR101455947B1 (es)
CN (1) CN103068388A (es)
AR (1) AR084401A1 (es)
AU (1) AU2011288536B2 (es)
BR (1) BR112013003068A2 (es)
CA (1) CA2803656A1 (es)
CL (1) CL2013000378A1 (es)
CR (1) CR20130027A (es)
CY (1) CY1115886T1 (es)
DK (1) DK2603219T3 (es)
EA (1) EA201291477A1 (es)
EC (1) ECSP13012431A (es)
ES (1) ES2521596T3 (es)
HR (1) HRP20141199T1 (es)
MA (1) MA34457B1 (es)
MX (1) MX2013001166A (es)
NZ (1) NZ604891A (es)
PE (1) PE20131100A1 (es)
PH (1) PH12013500078A1 (es)
PL (1) PL2603219T3 (es)
PT (1) PT2603219E (es)
SG (1) SG187108A1 (es)
SI (1) SI2603219T1 (es)
TW (1) TW201211019A (es)
WO (1) WO2012019970A1 (es)
ZA (1) ZA201300434B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150158903A1 (en) 2011-09-08 2015-06-11 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
LT2968369T (lt) 2013-03-13 2018-12-27 Sage Therapeutics, Inc. Neuroaktyvūs steroidai ir jų panaudojimo būdai
EP3076953A1 (en) * 2013-12-03 2016-10-12 F. Hoffmann-La Roche AG Pharmaceutical composition
KR20160147868A (ko) * 2014-04-30 2016-12-23 위펑 제인 쳉 D-아미노산 옥시다제 억제제로서 공지된 화합물의 용도
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
EP3204011A4 (en) * 2014-10-07 2018-06-20 Sage Therapeutics, Inc. Neuroactive compounds and methods of use thereof
RS62220B1 (sr) 2015-07-06 2021-09-30 Sage Therapeutics Inc Oksisteroli i postupci njihovog korišćenja
MA42409A (fr) 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
MX376833B (es) 2015-07-06 2025-03-07 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
CN114272249A (zh) 2016-04-01 2022-04-05 萨奇治疗股份有限公司 氧甾醇及其使用方法
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2017292870B2 (en) 2016-07-07 2021-10-07 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3519422B1 (en) 2016-09-30 2022-08-31 Sage Therapeutics, Inc. C7 substituted oxysterols and these compounds for use as nmda modulators
KR20250054838A (ko) 2016-10-18 2025-04-23 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
ES2952106T3 (es) 2016-10-18 2023-10-27 Sage Therapeutics Inc Oxisteroles y procedimientos de utilización de los mismos
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
EP4545140A3 (en) * 2017-11-14 2025-07-09 SK Biopharmaceuticals Co., Ltd. Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004263306B2 (en) 2003-08-11 2010-04-22 F. Hoffmann-La Roche Ag Piperazine with or-substituted phenyl group and their use as GLYT1 inhibitors
WO2006000222A2 (en) * 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
BRPI0608148A2 (pt) * 2005-04-08 2009-11-10 Pfizer Prod Inc [3.1.01] heteroaril amidas bicìclicas como inibidores de transporte de glicina do tipo i,composição farmacêutica para tratamento de distúrbio e seu uso
GB0612420D0 (en) * 2006-06-22 2006-08-02 Glaxo Group Ltd Compounds
UA94615C2 (uk) * 2006-06-28 2011-05-25 Амген Інк. Інгібітори транспортера-1 гліцину

Also Published As

Publication number Publication date
EP2603219A1 (en) 2013-06-19
ES2521596T3 (es) 2014-11-13
CA2803656A1 (en) 2012-02-16
AR084401A1 (es) 2013-05-15
BR112013003068A2 (pt) 2016-06-28
CR20130027A (es) 2013-03-04
SI2603219T1 (sl) 2014-12-31
AU2011288536B2 (en) 2014-10-09
EP2603219B1 (en) 2014-09-17
KR20130045379A (ko) 2013-05-03
PT2603219E (pt) 2014-11-25
DK2603219T3 (da) 2014-10-13
CY1115886T1 (el) 2017-01-25
AU2011288536A1 (en) 2013-01-31
CL2013000378A1 (es) 2013-05-03
ZA201300434B (en) 2013-09-25
WO2012019970A1 (en) 2012-02-16
PL2603219T3 (pl) 2015-03-31
NZ604891A (en) 2015-01-30
SG187108A1 (en) 2013-02-28
JP2013533297A (ja) 2013-08-22
PH12013500078A1 (en) 2013-03-11
US20120035156A1 (en) 2012-02-09
KR101455947B1 (ko) 2014-10-28
CN103068388A (zh) 2013-04-24
PE20131100A1 (es) 2013-09-23
MA34457B1 (fr) 2013-08-01
TW201211019A (en) 2012-03-16
HRP20141199T1 (hr) 2015-02-13
MX2013001166A (es) 2013-03-22
EA201291477A1 (ru) 2013-06-28

Similar Documents

Publication Publication Date Title
ECSP13012431A (es) Combinación del compuesto glyt1 con antipsicóticos
ECSP14013169A (es) Tableta a prueba de alteración que proporciona liberación inmediata del fármaco
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
MX391175B (es) Macrociclos peptidomimeticos.
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
ECSP13013074A (es) Nuevos derivados de piridina
GT201200144A (es) Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina
MX2013000567A (es) Composiciones farmaceuticas de moduladores de c-met.
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
GT201200230A (es) Inhibidores del virus de la hepatitis c
EA201590807A1 (ru) Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций
PE20142182A1 (es) Inhibidores de iap
BR112013028512A2 (pt) cápsula
CO6761298A2 (es) Combinaciones que comprenden antipsicóticos atípocos y antagonistas taar1
CR20150204A (es) Nuevos derivados de piridina
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
MX2015001553A (es) Composiciones y metodos para reducir el contenido de alcohol en sangre.
MX2015014757A (es) Derivados de purina como agonistas del receptor de cannabinoides 2 (cb2).
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease
BR112014019220A8 (pt) Novos derivados de pirrolidina
SV2015004997A (es) Comprimidos que tienen aceptacion mejorada y buena estabilidad durante el almacenamiento
CR20150275A (es) Composición de difenidol de liberación prolongada
CU20150173A7 (es) COMPOSICIÓN FARMACÉUTICA QUE INCLUYE UN INHIBIDOR DE LA HMG-Coa REDUCTASA QUE MINIMIZA LA INTERACCIÓN DEL ÁCIDO ÁCIDO ACETILSALICÍLICO CON LA ESTATINA
BR112013029778A2 (pt) composição farmacêutica que compreende fexofenadina
BR112014011581A2 (pt) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de gpbar1